Cargando…
The role of brigatinib in crizotinib-resistant non-small cell lung cancer
Despite the advances in new targeted therapies in ALK positive population, most patients progress under ALK inhibitors within first 2 years; being the brain the most frequent site of relapse. ALK mutations, in ~30% of patients, are the main known mechanism of resistance. Classically, second-generati...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783011/ https://www.ncbi.nlm.nih.gov/pubmed/29403310 http://dx.doi.org/10.2147/CMAR.S129963 |